Osteoprotegerin and rank ligand expression in prostate cancer
- 1 April 2001
- Vol. 57 (4) , 611-616
- https://doi.org/10.1016/s0090-4295(00)01122-5
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cordNature Medicine, 2000
- RANK is essential for osteoclast and lymph node developmentGenes & Development, 1999
- Interleukin-1β and tumor necrosis factor-α, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cellsBone, 1999
- Osteomimetic properties of prostate cancer cells: A hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environmentThe Prostate, 1999
- Evidence for a Role of a Tumor Necrosis Factor-α (TNF-α)-converting Enzyme-like Protease in Shedding of TRANCE, a TNF Family Member Involved in Osteoclastogenesis and Dendritic Cell SurvivalPublished by Elsevier ,1999
- OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesisNature, 1999
- Transforming Growth Factor-β Stimulates the Production of Osteoprotegerin/Osteoclastogenesis Inhibitory Factor by Bone Marrow Stromal CellsJournal of Biological Chemistry, 1998
- Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and ActivationCell, 1998
- Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone DensityCell, 1997
- Morphometric Evidence for Bone Resorption and Replacement in Prostate CancerBritish Journal of Urology, 1991